MAIA Biotechnology, Inc.

Contributing Author

Recent Articles by MAIA Biotechnology, Inc.

Oct-27	MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics MAIA GlobeNewswire
Oct-23	MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer MAIA GlobeNewswire
Oct-13	MAIA Biotechnology Announces $736,600 Private Placement MAIA GlobeNewswire
Oct-07	MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets MAIA GlobeNewswire
Sep-29	MAIA Biotechnology Announces $2.25 Million Private Placement MAIA GlobeNewswire
Sep-24	MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent MAIA GlobeNewswire
Sep-11	MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer MAIA GlobeNewswire
Sep-05	MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer MAIA GlobeNewswire
Aug-27	MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells MAIA GlobeNewswire
Aug-13	MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy MAIA GlobeNewswire